For Diabetic Neuropathy – Recent study in China showed statistical significant drop of pain on Duloxetine but not clinically significant. – Have a look.
Gao Y, Guo X, Han P, et al.
Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
Int J Clin Pract. 2015 May 4 . doi: 10.1111/ijcp.12641.
- Diabetic neuropathy
- Duloxetine 60 mg/day
Results: – I have started the pain VAS graph from zero pain so results are more clear. There has to be a difference in pain between drug and placebo of at least VAS of 1 to be clinically significant. – It only got 0.5
To be fair, a previous double blind study just squeaked to drop VAS by 1 with 60 mg and even better at 120 mg. The latter dose was not well tolerated however.
I have been told that 2/10 might get substantial benefit from Cymbalta and it should be tried for such but combination therapy may need to be used to achieve substantive in most cases.